2022 BIO International Convention Innovation Zone Company Snapshot: Primetime Life Sciences
The 2022 BIO International Convention is back and in person this year. Thousands of global biotechnology and biopharmaceutical leaders will gather in San Diego as we celebrate how scientific discoveries and innovations are transforming our world. New technologies, therapies and vaccines are being developed in all corners of the world, by companies large and small. The NIH Innovation Zone will showcase nearly 30 NIH-funded small businesses and their cutting-edge work.
Attendees can visit the NIH Innovation Zone in the Innovation Stage, a new interactive forum that showcases the hottest companies in biotech. The Innovation Stage provides an engaging environment in which to hear from leading global innovators, regional economic development groups, the brightest biotech start-ups, and more.
We spoke with one Innovation Zone participant, Janak Padia, Ph.D., President & CEO of PrimeTime Life Sciences, which is an early-stage pharmaceutical company developing drugs to treat CNS disorders, cancer, bacterial infection, and parasitic diseases.
What is PrimeTime Life Sciences’ lead product or technology?
We are developing a first-in-class antidepressant that is rapid, effective, and safe. The company’s lead product is PTLS-181. It is a potent and selective A1R agonist. It has a rapid anti-depressive effect via rapid up-regulation of Homer1a in the mouse models. In addition, it has shown an excellent safety profile in toxicity studies.
How has the NIH SBIR program helped your company grow?
PrimeTime Life Sciences was awarded an NIH (NIMH) Fast-Track SBIR award of $2.9 M. This award allowed us to fund IND-enabling studies. We would not be able to progress this project without the NIH (NIMH) award. The NIH SBIR program also provided entrepreneur coaching and mentoring throughout the process.
What are the upcoming milestones and long-term priorities for PrimeTime Life Sciences?
We are currently progressing our lead compound, PTLS-181 through IND-enabling studies, which will be accomplished by the end of this year. Our next milestone is filing an IND application by the end of this year. Once we get the IND approval by FDA, we will be conducting clinical trials to study PTLS-181 as rapid and safe antidepressant in humans.
What do you hope to gain from your participation at the 2022 BIO International Convention?
We are hoping to discuss our project with potential partners and VCs for supporting clinical trials.
Tell us something about your company that investors might not know…
Primetime Life Sciences, LLC is an early-stage pharmaceutical company with cash positive business model. The company has assembled a founding group of executives with decades of experience in drug development and commercialization. The company is developing drugs to treat CNS disorders, cancer, bacterial infection, and parasitic diseases. In addition, Primetime Life Sciences has developed a mutual prodrug platform (Metual®) to discover New Molecular Entity (NME) prodrugs of known drugs with synergistic therapeutic effects and improved safety profiles.